Categories
Pharmaceutical

Demand for Fusion Protein Biosimilars is increasing for the Treatment of Cancer Market 2032 : Fact MR

Biologic drugs are commonly used to treat various diseases but their high cost has raised the emerging scope for biosimilars in the market. A fusion protein biosimilars has come forth as a new modality, as an alternate of biologic products. The fusion protein biosimilars combines the customized pharmacological properties of biological ligands, together with multiple functions of the fragmented crystallizable domain of immunoglobulins. The fusion protein biosimilars are used in several clinical studies based on applications like cancer, HIV-AIDS, chronic inflammatory diseases, and many other chronic diseases.

Request a report sample to gain comprehensive insights at  https://www.factmr.com/connectus/sample?flag=S&rep_id=5690

After proven effective against chronic diseases such as cancer, chronic inflammatory diseases, and cardiovascular, the demand for fusion protein biosimilar is expected to surge in the forecasting period.

More than 11 fusion protein drugs have been approved by the Food and Drug Administration (FDA) and several new Fc fusion proteins are in the developing stage. This increasing approval of novel new biosimilar drugs has presented a lucrative growth opportunity for the fusion proteins drugs market.

“To strengthen their footprint in the global market, key manufactures have increased their focus on the developing of more effective biosimilars drugs. Besides this, new product launches and collaboration with other companies will assist them to expand their regional presence and existing product portfolio,” says the Fact.MR analyst.

Key Takeaways

  • In Europe, the U.K. dominates the fusion protein biosimilars market owing to the presence of a well-defined regulatory framework.
  • Increasing approval of new biosimilar drugs is driving the growth in the U.S.
  • Due to the increasing industrial biologic development and ongoing improvement in the regulatory environment, the demand for fusion protein biosimilar is expected to surge in developed economies.
  • Owing to the increasing prevalence of chronic diseases and the rapidly expanding healthcare infrastructure, Asia Pacific has emerged as the fastest-growing fusion protein biosimilars market

Key Drivers

  • Surging incidence of chronic diseases will propel the demand for fusion protein biosimilars globally.
  • Favorable regulatory scenarios and expansion of the healthcare infrastructure are driving the biosimilars market.
  • Growing number of approvals and product launches will fuel the growth of the market.

Key Restraints

  • The side effects associated with prescribed drugs are hindering the demand for fusion protein biosimilars.
  • Strict regulatory approvals is the factor restraining the growth of the fusion protein biosimilars market.

Competitive Landscape

Prominent players in the market include Pfizer Inc., Eli Lilly and Company, Sandoz International GmbH, F. Hoffmann-La Roche Ltd., AbbVie Inc., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis, Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Fresenius Kabi AG, STADA Arzneimittel AG, Celltrion Healthcare Co.Ltd., Thermo Fisher Scientific Inc., Daiichi Sankyo Co Ltd., Aurobindo Pharma, Absolute Antibody, and Bioverativ Therapeutics Inc. Key players are acquiring and collaborating with other companies to gain maximum revenue share and expand their regional presence. For instance,

  • SOTIO had acquired Cytune Pharma to allow the company the usage of Cytune’s SO-C101 in 2018.
  • In January 2020, Coherus BioSciences, Inc. entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd

Get Customization on this Report for Specific Country https://www.factmr.com/connectus/sample?flag=RC&rep_id=5690

More Insights on the Fusion Protein Biosimilars Market

Fact.MR has published unbiased analysis of the fusion protein biosimilars market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (cytokines recombinant protein, immunoglobin (Ig) fusion protein, parathyroid hormone (PTPH) fusion protein), application (cancer, HIV-AIDS, respiratory disease, cardiovascular disorder, and ophthalmology)
end user (hospitals and Research institutes), across seven regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa).

Read More Trending Reports of Fact.MR-

https://www.einpresswire.com/article/557298123/demand-for-independent-front-suspension-is-estimated-to-remain-high-owing-to-the-system-of-better-handling-stability

Why choose Fact.MR?

Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.

Explore Fact.MR’s Comprehensive Coverage on Healthcare Domain:

Fluoro Enzymatic Assays Market – https://www.factmr.com/report/fluoro-enzymatic-assays-market

Shower Chairs Market – https://www.factmr.com/report/shower-chairs-market

Infrared Thermometer Market – https://www.factmr.com/report/infrared-thermometer-market

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

4-1-1 Nakano,
9F Nakano Sunplaza
Tokyo, 164-8512
Japan

Tel: +1 (888) 863-5616

E-Mail: sales@factmr.com

 

Categories
Pharmaceutical

Demand for Fusion Protein Biosimilars is increasing for the Treatment of Cancer: Fact MR

The global fusion protein biosimilar market is exhibiting steady growth due to increasing investment in research and development initiatives. Besides this, increasing applications of fusion protein biosimilar for treatment of various diseases will result in significant growth of the market.

According to Globo can, more than 19,292,789 cases of cancer were reported in the year 2020. Around 9,958,133 deaths were recorded in the year 2020 due to cancers. Cancer is estimated to hold the highest share in the fusion protein biosimilars market on the back of rising incidence registered around the world.

After proven effective against chronic diseases such as cancer, chronic inflammatory diseases, and cardiovascular, the demand for fusion protein biosimilar is expected to surge in the forecasting period.

More than 11 fusion protein drugs have been approved by the Food and Drug Administration (FDA) and several new Fc fusion proteins are in the developing stage. This increasing approval of novel new biosimilar drugs has presented a lucrative growth opportunity for the fusion proteins drugs market.

“To strengthen their footprint in the global market, key manufactures have increased their focus on the developing of more effective biosimilars drugs. Besides this, new product launches and collaboration with other companies will assist them to expand their regional presence and existing product portfolio,” says the Fact.MR analyst.

Request a report sample to gain comprehensive insights at  https://www.factmr.com/connectus/sample?flag=S&rep_id=5690

Key Takeaways

  • In Europe, the U.K. dominates the fusion protein biosimilars market owing to the presence of a well-defined regulatory framework.
  • Increasing approval of new biosimilar drugs is driving the growth in the U.S.
  • Due to the increasing industrial biologic development and ongoing improvement in the regulatory environment, the demand for fusion protein biosimilar is expected to surge in developed economies.
  • Owing to the increasing prevalence of chronic diseases and the rapidly expanding healthcare infrastructure, Asia Pacific has emerged as the fastest-growing fusion protein biosimilars market

Key Drivers

  • Surging incidence of chronic diseases will propel the demand for fusion protein biosimilars globally.
  • Favorable regulatory scenarios and expansion of the healthcare infrastructure are driving the biosimilars market.
  • Growing number of approvals and product launches will fuel the growth of the market.

Key Restraints

  • The side effects associated with prescribed drugs are hindering the demand for fusion protein biosimilars.
  • Strict regulatory approvals is the factor restraining the growth of the fusion protein biosimilars market.

Competitive Landscape

Prominent players in the market include Pfizer Inc., Eli Lilly and Company, Sandoz International GmbH, F. Hoffmann-La Roche Ltd., AbbVie Inc., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis, Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis AG, Fresenius Kabi AG, STADA Arzneimittel AG, Celltrion Healthcare Co.Ltd., Thermo Fisher Scientific Inc., Daiichi Sankyo Co Ltd., Aurobindo Pharma, Absolute Antibody, and Bioverativ Therapeutics Inc. Key players are acquiring and collaborating with other companies to gain maximum revenue share and expand their regional presence. For instance,

  • SOTIO had acquired Cytune Pharma to allow the company the usage of Cytune’s SO-C101 in 2018.
  • In January 2020, Coherus BioSciences, Inc. entered into a licensing agreement with Innovent Biologics, (Suzhou) Co., Ltd

Get Customization on this Report for Specific Country https://www.factmr.com/connectus/sample?flag=RC&rep_id=5690

More Insights on the Fusion Protein Biosimilars Market

Fact.MR has published unbiased analysis of the fusion protein biosimilars market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (cytokines recombinant protein, immunoglobin (Ig) fusion protein, parathyroid hormone (PTPH) fusion protein), application (cancer, HIV-AIDS, respiratory disease, cardiovascular disorder, and ophthalmology)
end user (hospitals and Research institutes), across seven regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa).

Explore Fact.MR’s Coverage on the Healthcare Domain:

Shower Chairs Market – Fact.MR- market research and competitive intelligence provider, projects that increasing safety awareness for the elderly and disabled during bathing is pushing up global shower chairs demand, expanding at a noteworthy pace from 2021-2031.

Infrared Thermometer Market – As per Fact.MR’s recent report, the infrared thermometer market is set to observe an exponential growth over the forecast period 2021-2031. Increasing growth in demand and sales is expected to influence the sales of infrared thermometers positively.

COVID Alert Apps Market – As per a report by Fact.MR, the COVID alert app market will observe substantial growth, but for a limited period of time. This is mainly due to the varying number of active infection cases in different regions.

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Categories
Pharmaceutical

Global Fusion Protein Biosimilars Market (2021-2031) To Register Substantial Global Expansion By 2031

The Global Fusion Protein Biosimilars Market provides scrutiny of various growth trajectories of the market and its segments during the forecast period (2021 – 2031). The analysts strive to offer a comprehensive insight into consumer adoption trends, and the corresponding strategies by players to acquire more shares. The insights include a granular assessment of favorable policy regulations and norms. The study in addition takes a closer look at the key macroeconomic fundamentals in various regions that will spur investments in the Fusion Protein Biosimilars market. The research offers a qualitative assessment of the recent disruptions and the strategy realignments to counter the forces restraining the growth of the Fusion Protein Biosimilars market.

The emerging pandemic of novel Coronavirus or Covid-19 as it is popularly now known has posed immense repercussions on the macro-economy fundamentals of several countries across the world. Supply chain and production disruptions on various markets due to Covid-19 have been scrutinized by policymakers, especially of developing and developed countries. Over the past few months, they have been intensifying their focus on adopting regulatory frameworks and offering financial stimulus that will inspire confidence among investors across key sectors. The Fusion Protein Biosimilars market analysts also take a closer look at the game-changing potential the current pandemic has and the trends that will revive market sentiments. The study on the Fusion Protein Biosimilars market also aims to offer scenario planning for CXOs of businesses across the industries that shape the market. The report offers an evidence-based analysis of the implication of Covid-19 restrictions on market dynamics.

Get Request for PDF Brochure of This Market Research Report @ https://www.factmr.com/connectus/sample?flag=B&rep_id=5690

The report study also makes inclusion of SWOT analysis and PESTEL analysis of the said industry. The study incorporates a market attractiveness analysis, in which all of the segments have been benchmarked based on their growth rate, market size, and general attractiveness in terms of incremental value growth and investment opportunity.

To understand of the competitive landscape in the Global Fusion Protein Biosimilars Market better, the report covers the profile of the following top players:

Pfizer Inc., Eli Lilly and Company, Sandoz International GmbH, F. Hoffmann-La Roche Ltd., AbbVie Inc., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis, Teva Pharmaceutical Industries Ltd., Mylan N.V.,  Novartis AG, Fresenius Kabi AG, STADA Arzneimittel AG, Celltrion Healthcare Co.Ltd., Thermo Fisher Scientific Inc., Daiichi Sankyo Co Ltd., Aurobindo Pharma, Absolute Antibody, Bioverativ Therapeutics Inc.

GLOBAL FUSION PROTEIN BIOSIMILARS MARKET: SEGMENTATION

  • Based on the product, the fusion protein biosimilars market has been segmented as
    • Cytokines Recombinant protein
    • Immunoglobin (Ig) fusion protein
    • Parathyroid Hormone (PTPH) fusion protein
    • Others
  • Based on application, the fusion protein biosimilars market has been segmented as
    • Cancer
    • HIV-AIDS
    • Respiratory disease
    • Cardiovascular disorder
    • Ophthalmology
    • Others
  • Based on end-users, the fusion protein biosimilars market has been segmented as
    • Hospitals
    • Research institutes

The global Fusion Protein Biosimilars market report covers the following regions: 

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC Countries, S. Africa, Northern Africa)

Get Request for Report Customization @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=5690

A detailed assessment of the growth dynamics includes opportunities and growth trends. Some of the questions pertain to these are answered in the study:

  • Key investment avenues in emerging economies
  • Strategy realignments to counter the implications of the Covid-19 pandemic
  • Products with new profit avenues and emerging business models to support their demand in the Fusion Protein Biosimilars market
  • Entry of new players and the strategies they adopt to surge ahead in the competition
  • Share and revenue size of key end-use industry or application segments year-over-year

The report on the Fusion Protein Biosimilars market is unique in its approach and insights-gathering initiatives. Some of the aspects that the study highlight are:

  • The study offers insight into key cost–optimization strategies and guides into their implementation
  • Insights into the new normal that have come to the fore due to COVID-19
  • Strategies that will help market players achieve resilience in the near future
  • The Fusion Protein Biosimilars market report offers a framework for understanding the complexity of budgets allotments of companies across vendors, distributors, and logistics partners in the Fusion Protein Biosimilars market
  • Investments that drive digital workplace technologies being adopted in the industry landscape

The report gives an objective and pragmatic outlook on key trends pertaining to:

  • Consumer buying patterns and propensities
  • Changes in consumer sentiment due to the pandemic and other subsidiary factors
  • The net change in market demand over the past years
  • The leading industrial trends that have contributed to market maturity
  • Use of new technologies and development of fresh products/services by the vendors

Enquiry before Buying @ https://www.factmr.com/connectus/sample?flag=EB&rep_id=5690

The report answers, in detail, the following key questions pertaining to market expansion:

  • Which regulatory compliances are essential for legally existing and entering into the market?
  • Which factors could be a threat, opportunity, or untapped territory for the market vendors?
  • Which regions are expected to offer fresh opportunities for establishing footholds in the market?
  • What are the odds and opportunities of remaining in the market despite the challenges and disruptions?

The report addresses the following doubts related to the Fusion Protein Biosimilars Market:

  1. Which company in the Fusion Protein Biosimilars market is leading in terms of innovation?
  2. The demand from which end-user is expected to drive the growth of the Fusion Protein Biosimilars market?
  3. What are the growth opportunities for market players in the developing regions?
  4. What are the various distribution channels adopted by market players in the Fusion Protein Biosimilars market?
  5. How are emerging market players establishing their presence in the current market landscape?

More Related Reports By Fact.MR On Healthcare Domain:

Fractional Flow Reserve-computed Tomography (FFR-CT) Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030

Arterial Stabilization Device Market Forecast, Trend Analysis, & Competition Tracking – Global Review 2020 to 2030

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583

Corporate Headquarter:

Unit No: AU-01-H Gold Tower (AU),

Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers,

Dubai, United Arab Emirates

Email: sales@factmr.com

Visit Our Website: https://www.factmr.com